Evaluation of mycophenolate mofetil as a steroid-sparing agent in pemphigus: A randomized, prospective study

Journal of the European Academy of Dermatology and Venereology

Volumn 26, Issue 7, 2012, Pages 855-860

  Ioannides, D ^a   Apalla, Z ^a   Lazaridou, E ^a   Rigopoulos, D ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; DERMATOLOGICAL AGENT; DRUG DERIVATIVE; MYCOPHENOLIC ACID;

ADD ON THERAPY; ADULT; AGED; ARTICLE; BLOOD TOXICITY; CLINICAL ARTICLE; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DISEASE ACTIVITY; DRUG DOSE INCREASE; DRUG EFFICACY; EYE DISEASE; FATIGUE; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; HUMAN; HYPERTENSION; INFECTION; MALE; MONOTHERAPY; MORNING DOSAGE; MUSCLE WEAKNESS; PEMPHIGUS; PEMPHIGUS FOLIACEUS; PEMPHIGUS VULGARIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RELAPSE; REMISSION; SIDE EFFECT; TREATMENT RESPONSE; WEIGHT GAIN; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; MIDDLE AGED;

ADULT; AGED; DERMATOLOGIC AGENTS; FEMALE; HUMANS; MALE; METHYLPREDNISOLONE; MIDDLE AGED; MYCOPHENOLIC ACID; PEMPHIGUS; PROSPECTIVE STUDIES;

EID: 84862757880     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2011.04170.x     Document Type: Article

References (20)

1. Bystryn JC, Rudolph JL,. Pemphigus. Lancet 2005; 366: 61-73. (Pubitemid 40956532)
2. Ioannides D, Lazaridou E, Rigopoulos D,. Pemphigus. J Eur Acad Dermatol Venereol 2008; 22: 1478-1496.
3. Murrell DF, Dick S, Ahmed AR, et al. Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus. J Am Acad Dermatol 2008; 58: 1043-1046.
4. Mimouni D, Nousari CH, Cummins DL, et al. Differences and similarities among expert opinions on the diagnosis and treatment of pemphigus vulgaris. J Am Acad Dermatol 2003; 49: 1059-1062. (Pubitemid 37475477)
5. Bystryn JC,. Is mycophenolic acid effective for the treatment of pemphigus? Arch Dermatol 1999; 135: 854-855.
6. Ioannides D, Chrysomallis F, Bystryn JC,. Ineffectiveness of cyclosporine as an adjuvant to corticosteroids in the treatment of pemphigus. Arch Dermatol 2000; 136: 868-872. (Pubitemid 30604285)
7. Chams-Davatchi C, Esmaili N, Daneshpazhooh M, et al. Randomized controlled open-label trial of four treatment regimens for pemphigus vulgaris. J Am Acad Dermatol 2007; 57: 622-628. (Pubitemid 47384928)
8. Powell AM, Albert S, Al Fares S, et al. An evaluation of the usefulness of mycophenolate mofetil in pemphigus. Br J Dermatol 2003; 149: 138-145. (Pubitemid 36966523)
9. Esmaili N, Chams-Davatchi C, Valikhani M, et al. Treatment of pemphigus vulgaris with mycophenolate mofetil as a steroid-sparing agent. Eur J Dermatol. 2008; 18: 159-164. (Pubitemid 351554804)
10. Beissert S, Werfel T, Frieling U, et al. A comparison of oral methylprednisolone plus azathioprine or mycophenolate mofetil for the treatment of pemphigus. Arch Dermatol 2006; 142: 1447-1454. (Pubitemid 44790638)
11. Mimouni D, Anhalt GJ, Cummins DL, et al. Treatment of pemphigus vulgaris and pemphigus foliaceus with mycophenolate mofetil. Arch Dermatol 2003; 139: 739-742. (Pubitemid 36705940)
12. Grundmann-Kollmann M, Korting HC, Behrens S, et al. Mycophenolate mofetil: a new therapeutic option in the treatment of blistering autoimmune diseases. J Am Acad Dermatol 1999; 40: 957-960. (Pubitemid 29268927)
13. Chams-Davatchi C, Nonahal AR, Daneshpazooh M, et al. [Open trial of mycophenolate mofetil in the treatment of resistant pemphigus vulgaris]. Ann Dermatol Venereol 2002; 129: 23-25. (Pubitemid 34193698)
14. Enk AH, Knop J,. Mycophenolate is effective in the treatment of pemphigus vulgaris. Arch Dermatol 1999; 135: 54-56. (Pubitemid 29069517)
15. Baskan EB, Yilmaz M, Tunali S, Saricaoglu H,. Efficacy and safety of long-term mycophenolate sodium therapy in pemphigus vulgaris. J Eur Acad Dermatol Venereol 2009; 23: 1432-1434.
16. Enk AH, Knop J,. Treatment of pemphigus vulgaris with mycophenolate mofetil. Lancet 1997; 350: 494. (Pubitemid 27343313)
17. Kawashita MY, Tsai K, Aoki V, et al. Mycophenolate mofetil as an adjuvant therapy for classic and endemic pemphigus foliaceus. J Dermatol 2005; 32: 574-580. (Pubitemid 41206440)
18. Bredlich RO, Grundmann-Kollmann M, Behrens S, et al. Mycophenolate mofetil monotherapy for pemphigus vulgaris. Br J Dermatol 1999; 141: 934.
19. Beissert S, Mimouni D, Kanwar AJ, et al. Treating pemphigus vulgaris with prednisone and mycophenolate mofetil: a multicenter, randomized, placebo-controlled trial. J Invest Dermatol 2010; 130: 2041-2048.
20. Martin LK, Werth VP, Villaneuva EV, Murrell DF,. A systematic review of randomized controlled trials for pemphigus vulgaris and pemphigus foliaceus. J Am Acad Dermatol 2011; 64: 903-908.